Ena Respiratory Company

Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.

Founded Date: 41640
Technology: diagnostics
Funding Status: Early Stage Venture
Employee Number: 11-50
Headquarters: Melbourne, Victoria, Australia
Last Funding Date: 2020-09-28
Last Funding Type: Series A
Estimated Revenue: $1M to $10M
Industry: Biotechnology, Health Diagnostics, Medical